Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, uppe… Read more
Market Cap & Net Worth: Marksans Pharma Limited (MARKSANS)
Marksans Pharma Limited (NSE:MARKSANS) has a market capitalization of $906.18 Million (₹78.48 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #11020 globally and #470 in its home market, demonstrating a 1.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Marksans Pharma Limited's stock price ₹173.18 by its total outstanding shares 453163746 (453.16 Million).
Marksans Pharma Limited Market Cap History: 2015 to 2026
Marksans Pharma Limited's market capitalization history from 2015 to 2026. Data shows growth from $533.66 Million to $906.18 Million (5.23% CAGR).
Index Memberships
Marksans Pharma Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$69.23 Billion | 0.62% | #60 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.39 Trillion | 0.03% | #401 of 750 |
Weight: Marksans Pharma Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Marksans Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Marksans Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
Marksans Pharma Limited's market cap is 0.04 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.25x
Marksans Pharma Limited's market cap is 0.25 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $203.59 Million | $8.93 Billion | $785.12 Million | 0.02x | 0.26x |
| 2017 | $204.33 Million | $7.67 Billion | $95.19 Million | 0.03x | 2.15x |
| 2018 | $142.64 Million | $9.13 Billion | $329.40 Million | 0.02x | 0.43x |
| 2019 | $85.82 Million | $9.87 Billion | $804.37 Million | 0.01x | 0.11x |
| 2020 | $312.33 Million | $11.29 Billion | $1.21 Billion | 0.03x | 0.26x |
| 2021 | $310.84 Million | $13.68 Billion | $2.39 Billion | 0.02x | 0.13x |
| 2022 | $302.48 Million | $14.80 Billion | $1.85 Billion | 0.02x | 0.16x |
| 2023 | $841.25 Million | $18.52 Billion | $2.66 Billion | 0.05x | 0.32x |
| 2024 | $1.55 Billion | $21.77 Billion | $3.14 Billion | 0.07x | 0.49x |
| 2025 | $943.39 Million | $26.23 Billion | $3.81 Billion | 0.04x | 0.25x |
Competitor Companies of MARKSANS by Market Capitalization
Companies near Marksans Pharma Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Marksans Pharma Limited by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Marksans Pharma Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Marksans Pharma Limited's market cap moved from $533.66 Million to $ 906.18 Million, with a yearly change of 5.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹906.18 Million | -3.94% |
| 2025 | ₹943.39 Million | -39.22% |
| 2024 | ₹1.55 Billion | +84.52% |
| 2023 | ₹841.25 Million | +178.12% |
| 2022 | ₹302.48 Million | -2.69% |
| 2021 | ₹310.84 Million | -0.48% |
| 2020 | ₹312.33 Million | +263.92% |
| 2019 | ₹85.82 Million | -39.83% |
| 2018 | ₹142.64 Million | -30.19% |
| 2017 | ₹204.33 Million | +0.36% |
| 2016 | ₹203.59 Million | -61.85% |
| 2015 | ₹533.66 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Marksans Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $906.18 Million USD |
| MoneyControl | $906.18 Million USD |
| MarketWatch | $906.18 Million USD |
| marketcap.company | $906.18 Million USD |
| Reuters | $906.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.